Shanghai Model Organisms Center Inc
SSE:688265
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Model Organisms Center Inc
Income from Continuing Operations
Shanghai Model Organisms Center Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Model Organisms Center Inc
SSE:688265
|
Income from Continuing Operations
¥6.5m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Income from Continuing Operations
¥19.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Income from Continuing Operations
¥1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Income from Continuing Operations
¥5.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Income from Continuing Operations
¥805.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
17%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Income from Continuing Operations
¥1.5B
|
CAGR 3-Years
112%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
Shanghai Model Organisms Center Inc
Glance View
Shanghai Model Organisms Center, Inc. provides life science research and drug discovery services for cancer immunotherapy. The company is headquartered in Shanghai, Shanghai and currently employs 509 full-time employees. The company went IPO on 2021-12-28. The firm's businesses include genetically modified animal model, model breeding, feeding service, efficacy evaluation and phenotypic analysis, other model biotechnology services, model purchase and sales business and other businesses. The genetically modified animal model products are divided into customized models and standardized models, mainly including genetically modified mouse models, genetically modified rat models, genetically modified nematode models and genetically modified zebrafish models. The model breeding business refers to the use of genetically modified animal models developed and produced by the issuer or existing genetically modified animal models provided by customers through natural breeding or assisted reproductive breeding.
See Also
What is Shanghai Model Organisms Center Inc's Income from Continuing Operations?
Income from Continuing Operations
6.5m
CNY
Based on the financial report for Dec 31, 2024, Shanghai Model Organisms Center Inc's Income from Continuing Operations amounts to 6.5m CNY.
What is Shanghai Model Organisms Center Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-23%
The average annual Income from Continuing Operations growth rates for Shanghai Model Organisms Center Inc have been -53% over the past three years , -23% over the past five years .